Aclaris Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.8 | $18.7 | $31.2 | $29.8 | $6.8 |
| Operating income | -$76.4 | -$141.9 | -$97.4 | -$89.9 | -$89.7 |
| Net income | -$64.9 | -$132.1 | -$88.5 | -$86.9 | -$90.9 |
| Cash Flow Statement | |||||
| Free cash flow | -$47.2 | -$20.2 | -$79.6 | -$68.2 | -$52.4 |
| Dividends | — | — | — | $0.0 | $0.0 |
Shares outstanding 147.2M · Free float 67.1%
Annual filing data through FY ended December 31, 2025; float as of September 11, 2026.